Hanmi Science Co Ltd
KRX:008930

Watchlist Manager
Hanmi Science Co Ltd Logo
Hanmi Science Co Ltd
KRX:008930
Watchlist
Price: 36 500 KRW 0.69% Market Closed
Market Cap: 2.5T KRW
Section:
 

Relative Value

The Relative Value of one Hanmi Science Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 36 500 KRW, Hanmi Science Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Hanmi Science Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
73
vs Industry
60
Median 3Y
1.9
Median 5Y
2.1
Industry
2.6
More Details
40.8
P/E
P/E
Price to Earnings
40.8
vs History
50
vs Industry
13
Median 3Y
31.3
Median 5Y
41.6
Industry
21.4
More Details
32.1
P/OCF
P/OCF
Price to OCF
32.1
vs History
87
vs Industry
18
Median 3Y
59.4
Median 5Y
103.8
Industry
16.4
More Details
39.3
P/FCFE
P/FCFE
Price to FCFE
39.3
vs History
87
vs Industry
16
Median 3Y
73.6
Median 5Y
188.5
Industry
22.8
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
74
vs Industry
33
Median 3Y
2.9
Median 5Y
3.1
Industry
2.2
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
74
vs Industry
58
Median 3Y
2.1
Median 5Y
2.2
Industry
2.9
More Details
10.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.2
vs History
77
vs Industry
25
Median 3Y
10.8
Median 5Y
12.8
Industry
5.5
More Details
50.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
50.7
vs History
66
vs Industry
8
Median 3Y
50.7
Median 5Y
65.6
Industry
13
More Details
62.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
62.2
vs History
65
vs Industry
7
Median 3Y
61.8
Median 5Y
83.2
Industry
16.5
More Details
33.6
EV/OCF
EV/OCF
Enterprise Value to OCF
33.6
vs History
87
vs Industry
17
Median 3Y
63.7
Median 5Y
111.3
Industry
15.6
More Details
41.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
41.5
vs History
87
vs Industry
17
Median 3Y
86.1
Median 5Y
176.6
Industry
18.7
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
74
vs Industry
38
Median 3Y
2.2
Median 5Y
2.5
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Hanmi Science Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hanmi Science Co Ltd
KRX:008930
2.5T KRW 1.9 40.8 50.7 62.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.3 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
KR
Hanmi Science Co Ltd
KRX:008930
Average P/E: 26.1
40.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Hanmi Science Co Ltd
KRX:008930
Average EV/EBITDA: 404.4
50.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Hanmi Science Co Ltd
KRX:008930
Average EV/EBIT: 1 717.8
62.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.